WO2024259250A3 - Modulateurs du récepteur 5-ht2a et leurs procédés d'utilisation - Google Patents

Modulateurs du récepteur 5-ht2a et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2024259250A3
WO2024259250A3 PCT/US2024/034032 US2024034032W WO2024259250A3 WO 2024259250 A3 WO2024259250 A3 WO 2024259250A3 US 2024034032 W US2024034032 W US 2024034032W WO 2024259250 A3 WO2024259250 A3 WO 2024259250A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
receptor modulators
ht2a receptor
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/034032
Other languages
English (en)
Other versions
WO2024259250A2 (fr
Inventor
Paul Galatsis
Urjita H. SHAH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transneural Therapeutics Inc
Original Assignee
Transneural Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transneural Therapeutics Inc filed Critical Transneural Therapeutics Inc
Priority to CN202480053782.7A priority Critical patent/CN121843926A/zh
Publication of WO2024259250A2 publication Critical patent/WO2024259250A2/fr
Publication of WO2024259250A3 publication Critical patent/WO2024259250A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés, par exemple, des composés de formule I, et leur utilisation dans le traitement de maladies ou de troubles médicaux, tels que des troubles psychiatriques et neurologiques. L'invention concerne des compositions pharmaceutiques et des procédés de fabrication de divers composés de benzisoxazole et de benzoisothiazole. Les composés sont envisagés pour être des modulateurs du récepteur de la 5-hydroxytryptamine 2A (5-HT2A).
PCT/US2024/034032 2023-06-16 2024-06-14 Modulateurs du récepteur 5-ht2a et leurs procédés d'utilisation Ceased WO2024259250A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480053782.7A CN121843926A (zh) 2023-06-16 2024-06-14 5-ht2a受体调节剂及其使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508569P 2023-06-16 2023-06-16
US63/508,569 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024259250A2 WO2024259250A2 (fr) 2024-12-19
WO2024259250A3 true WO2024259250A3 (fr) 2025-04-10

Family

ID=93852768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034032 Ceased WO2024259250A2 (fr) 2023-06-16 2024-06-14 Modulateurs du récepteur 5-ht2a et leurs procédés d'utilisation

Country Status (2)

Country Link
CN (1) CN121843926A (fr)
WO (1) WO2024259250A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US20060252768A1 (en) * 2003-03-26 2006-11-09 Kazutoshi Watanabe 2,3,6-Trisubstituted-4-pyrimidone derivatives
US20200262916A1 (en) * 2019-02-15 2020-08-20 Stc. Unm Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES
WO2023141225A1 (fr) * 2022-01-19 2023-07-27 Onsero Therapeutics Inc. Hétérocycles fusionnés utilisés en tant qu'agonistes du récepteur 5-ht2a

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US20060252768A1 (en) * 2003-03-26 2006-11-09 Kazutoshi Watanabe 2,3,6-Trisubstituted-4-pyrimidone derivatives
US20200262916A1 (en) * 2019-02-15 2020-08-20 Stc. Unm Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES
WO2023141225A1 (fr) * 2022-01-19 2023-07-27 Onsero Therapeutics Inc. Hétérocycles fusionnés utilisés en tant qu'agonistes du récepteur 5-ht2a

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubchem 12 February 2015 (2015-02-12), "SCHEMBL795369", XP093303835, Database accession no. SID 227075288 *
SHASTRI, RA: "Review on Synthesis of 3-Substituted 1,2-Benzisoxazole Derivatives", CHEMICAL SCIENCE TRANSACTIONS, vol. 5, no. 1, 2016, pages 8 - 20, XP055581116, DOI: 10.7598/cst2016.1120 *
SIVALA MUNICHANDRA REDDY, CHINTHA VENKATARAMAIAH, POTLA KRISHNA MURTHY, CHINNAM SAMPATH, CHAMARTHI NAGA RAJU: "In silico docking studies and synthesis of new phosphoramidate derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole as potential antimicrobial agents", JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH., MARCEL DEKKER, NEW YORK, NY., US, vol. 40, no. 5, 1 September 2020 (2020-09-01), US , pages 486 - 492, XP009562410, ISSN: 1079-9893, DOI: 10.1080/10799893.2020.1752719 *

Also Published As

Publication number Publication date
WO2024259250A2 (fr) 2024-12-19
CN121843926A (zh) 2026-04-10

Similar Documents

Publication Publication Date Title
WO2024120378A3 (fr) Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci
NO20063787L (no) Terapeutiske preparater
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
TW200502221A (en) Novel lactams and uses thereof
WO2004087677A3 (fr) Pyrimidinones substituees
WO2003093250A3 (fr) Modulateurs allosteriques positifs de recepteur nicotinique de l'acetylcholine
CA2417897A1 (fr) Heterocycles bicycliques, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire
WO2005021519A3 (fr) Composes organiques
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
WO2005037798A3 (fr) Nouveaux composés
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
WO2019217890A8 (fr) Nouveaux lactames fonctionnalisés en tant que modulateurs du récepteur de 5-hydroxytryptamine 7 et leur procédé d'utilisation
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
EP1725536B8 (fr) Derives de l'imidazoline presentant une activite antagoniste cb1
TW200633986A (en) Therapeutic agents
WO2003070728A3 (fr) Composes aryle substitues permettant de traiter une maladie
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2022204344A3 (fr) N-oxydes d'énamine : synthèse et application à des promédicaments sensibles à l'hypoxie et agents d'imagerie
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2026521373

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE